IDN Decision Making on New Testing Protocols for Type 1 Diabetes
I'd like to understand the key drivers and barriers influencing integrated delivery networks' (IDN) decisions to adopt new testing protocols to screen and identify type 1 diabetes (T1D) patients (including among misdiagnosed T2D patients). I'd also like to discuss as well which IDN stakeholders need to be at the table to drive adoption.
We are looking for perspectives from Endocrinology or primary care department heads, Heads of Clinical Labs, Directors of Finance, EHR/EMR / Technology specialists, and also Population Health contacts.
This is a multi-faceted discussion so a variety of stakeholders are needed.